| Autor: |
Ildikó Gágyor, Alastair D Hay, Tobias Dreischulte, Mark H Ebell, Guido Schmiemann, Antonius Schneider, Susann Hueber, Thomas Kühlein, Marco Roos, Stefanie Stark, Jochen Gensichen, Adolfo Figueiras, Linda Sanftenberg, Klaus Linde, Alexander Hapfelmeier, Lisette Warkentin, Stefanie Eck, Gábor Borgulya, Eva Bucher, Isabell Endrich, Christian Kretzschmann, Oliver Kurzai, Thien-Tri Lam, Orietta Massidda, Anne Simmenroth, Andrea Baumgärtel, Melanie Bößenecker, Merle Klanke, Kathrin Lasher, Klara Lorenz-Dant, Til Uebel, Fabian Walter, Peter K Kurotschka |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
BMJ Open, Vol 14, Iss 3 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2044-6055 |
| DOI: |
10.1136/bmjopen-2023-079345 |
| Popis: |
Introduction Uncomplicated urinary tract infections (uUTIs) in women are common infections encountered in primary care. Evidence suggests that rapid point-of-care tests (POCTs) to detect bacteria and erythrocytes in urine at presentation may help primary care clinicians to identify women with uUTIs in whom antibiotics can be withheld without influencing clinical outcomes. This pilot study aims to provide preliminary evidence on whether a POCT informed management of uUTI in women can safely reduce antibiotic use.Methods and analysis This is an open-label two-arm parallel cluster-randomised controlled pilot trial. 20 general practices affiliated with the Bavarian Practice-Based Research Network (BayFoNet) in Germany were randomly assigned to deliver patient management based on POCTs or to provide usual care. POCTs consist of phase-contrast microscopy to detect bacteria and urinary dipsticks to detect erythrocytes in urine samples. In both arms, urine samples will be obtained at presentation for POCTs (intervention arm only) and microbiological analysis. Women will be followed-up for 28 days from enrolment using self-reported symptom diaries, telephone follow-up and a review of the electronic medical record. Primary outcomes are feasibility of patient enrolment and retention rates per site, which will be summarised by means and SDs, with corresponding confidence and prediction intervals. Secondary outcomes include antibiotic use for UTI at day 28, time to symptom resolution, symptom burden, number of recurrent and upper UTIs and re-consultations and diagnostic accuracy of POCTs versus urine culture as the reference standard. These outcomes will be explored at cluster-levels and individual-levels using descriptive statistics, two-sample hypothesis tests and mixed effects models or generalised estimation equations.Ethics and dissemination The University of Würzburg institutional review board approved MicUTI on 16 December 2022 (protocol n. 109/22-sc). Study findings will be disseminated through peer-reviewed publications, conferences, reports addressed to clinicians and the local citizen’s forums.Trial registration number ClinicalTrials.gov NCT05667207. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
